0001415889-24-015138.txt : 20240603 0001415889-24-015138.hdr.sgml : 20240603 20240603160455 ACCESSION NUMBER: 0001415889-24-015138 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240530 FILED AS OF DATE: 20240603 DATE AS OF CHANGE: 20240603 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cavanaugh Sarah CENTRAL INDEX KEY: 0001709113 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15006 FILM NUMBER: 241013562 MAIL ADDRESS: STREET 1: C/O CELLDEX THERAPEUTICS, INC. STREET 2: 53 FRONTAGE ROAD, SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Celldex Therapeutics, Inc. CENTRAL INDEX KEY: 0000744218 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 133191702 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 BUSINESS PHONE: 908-200-7500 MAIL ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 FORMER COMPANY: FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19980828 FORMER COMPANY: FORMER CONFORMED NAME: T CELL SCIENCES INC DATE OF NAME CHANGE: 19920703 4 1 form4-06032024_080652.xml X0508 4 2024-05-30 0000744218 Celldex Therapeutics, Inc. CLDX 0001709113 Cavanaugh Sarah C/O CELLDEX THERAPEUTICS, INC. 53 FRONTAGE ROAD, SUITE 220 HAMPTON NJ 08827 false true false false SVP OF CORP AFFAIRS & ADMIN. 0 Common Stock 2024-05-30 4 M 0 10750 2.78 A 12610 D Common Stock 2024-05-30 4 M 0 10103 9.0165 A 22713 D Common Stock 2024-05-30 4 S 0 20853 33.7282 D 1860 D Incentive Stock Option (Right to Buy) 2.78 2024-05-30 4 M 0 10750 0 D 2029-06-19 Common Stock 10750 0 D Incentive Stock Option (Right to Buy) 9.0165 2024-05-30 4 M 0 10103 0 D 2028-06-13 Common Stock 10103 0 D Includes 576 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.465 to $34.06 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. As of June 19, 2023, the option is fully vested. As of June 13, 2022, the option is fully vested. /s/ Sam Martin, attorney-in-fact for Sarah Cavanaugh 2024-06-03